HRP conjugated Anti-SN38 Antibody, mAb | SN8-PLS223-200ug

HRP conjugated Anti-SN38 Antibody, mAb | SN8-PLS223-200ug| Gentaur Distribution US, UK & Europe

SN-38 is an antineoplastic drug. It is the active metabolite of irinotecan (an analog of camptothecin - a topoisomerase I inhibitor) but has 1000 times more activity than irinotecan itself. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. SN38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1. The variant of UGT1A1 in ~10% of Caucasians which leads to poor metabolism of SN-38 predicts irinotecan toxicity, as it is then less easily excreted from the body in its SN-38 glucuronide form. SN-38 and its glucuronide are lost into the bile and intestines. It can cause the symptoms of diarrhoea and myelosuppression experienced by ~25% of the patients administered irinotecan.

Source: HRP conjugated AntiN/ASN38 Antibody, is produced from a hybridoma resulting from fusion of SP2/0 myeloma and BN/Alymphocytes obtained from a mouse immunized with SN38.

Molecule: SN38.

Species: Mouse.

Tag: Mouse IgG1 | Mouse kappa.

Conjugate: HRP Labeled.

Purity: 90%.

Charactirization: PBS, pH7.4.

Storage Conditions: -20℃, aviod light.

Shipping Conditions: RT